AstraZeneca's Trixeo Aerosphere Receives CHMP's Recommendation for Approval to Treat COPD
Shots:
- The CHMP’s positive opinion is based on P-III ETHOS & KRONOS studies- which are a part of AstraZeneca’s P-III ATHENA program assessing Trixeo Aerosphere in 15500+ patients globally across 11 trials
- P-III ETHOS study results reported that triple-combination therapy showed a reduction in the rate of moderate or severe exacerbations compared with the Bevespi Aerosphere over 52wks. In both trials- the safety and tolerability of Trixeo Aerosphere were consistent with the profiles of the dual comparators
- Trixeo Aerosphere is a single-inhaler- fixed-dose triple combination of formoterol fumarate- glycopyrronium bromide with budesonide- delivered in a pressurized metered-dose inhaler- and is approved under the brand name Breztri Aerosphere in Japan- China & the US for COPD
Ref: AstraZeneca | Image: New Europe
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com